New drug combo may help kids with rare immune disease reach Life-Saving transplant
NCT ID NCT02472054
First seen Apr 03, 2026 · Last updated Jun 08, 2026 · Updated 11 times
Summary
This study tested the drug alemtuzumab as a first treatment for children with hemophagocytic lymphohistiocytosis (HLH), a rare and life-threatening immune disorder. The goal was to see if the drug could keep patients alive long enough to receive a stem cell transplant. The trial included 29 children under 18 with confirmed HLH, and measured survival and remission rates before transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hôpital Necker-Enfants Malades
Paris, 75015, France
Conditions
Explore the condition pages connected to this study.